[ad_1]
- Founded in 2019, under the leadership of its high-profile industry-leading founders, Cureleads is committed to transforming the lives of patients across the MENA region by leading the way in the treatment of specialty and rare diseases.
Dubai, UAE: Abdul Latif Jameel Health, part of the internationally diversified family-owned Abdul Latif Jameel, Cureleads, a pharmaceutical and pharmaceutical distribution and marketing business based in Dubai, UAE, and Beirut, Lebanon, with operations in the Middle East and North Africa, announced a new Distribution agreement for Butterfly Network, Inc.’s Butterfly iQ+ ultrasound solution in the UAE.
Innovative Butterfly iQ+[1] is the world’s first single-probe, whole-body handheld ultrasound solution, bringing the power of ultrasound to the assessment, diagnosis and treatment process.
As part of a new agreement with Abdul Latif Jameel Health, Cureleads will register Butterfly iQ+ in the United Arab Emirates, already widely considered the healthcare hub of the Middle East, with commercial sales commencing in December 2022, making the technology potentially beneficial to More than 26,000 patients Doctors practicing in public and private hospitals and facilities across the UAE[2].
More than 4.7 billion people worldwide lack access to medical imaging, according to the World Health Organization[3], from underserved communities in the United States to remote areas in Africa. Butterfly iQ+ aims to rectify this situation. Butterfly’s fusion of semiconductors and artificial intelligence enabled a new era of medical imaging and, in turn, transformed healthcare.
With a very diverse population, the study estimates that the UAE’s population will reach 10.08 million in 2022, more than double the 2005 population of 4.58 million[4]. Government figures report that more than 200 nationalities live and work in the UAE. Indians are the largest foreign community in the country, followed by Pakistanis, Bangladeshis, other Asians, Europeans and Africans.[5]
This new collaboration will provide physicians in the UAE with increased distribution of Butterfly iQ+, expanding the capacity of practitioners working in and outside of primary care settings such as hospitals and clinics, accelerating the delivery of modern healthcare to those who need it most.
Butterfly iQ+, is revolutionizing medical imaging. It is an innovative 3-in-1, single-probe, whole-body handheld ultrasound solution powered by the world’s only Ultrasound–on-Chip™ technology.
This point-of-care device with more than 20 default presets is compatible with iOS and Android smart devices and features battery backup, wireless charging, custom app software, and AI support.
Hailed as a potential “stethoscope of the future,” the Butterfly iQ+ transforms what can sometimes be a complex process into a connected and integrated bedside imaging system. Butterfly iQ+ uniquely unlocks access to ultrasound information in every point-of-care setting, no matter where that setting is located.
Through this distribution, clinicians across the UAE will have access to information they never had before, enabling them to conduct rapid assessments and guide more informed clinical decisions, diagnosis and treatment.
Commenting on the new collaboration, Mohamad Rammal, CEO and co-founder of Cureleads, said: “My purpose in life, and that of Cureleads, is to create happy, healthy and meaningful lives. Our goal is to change the lives of patients by leading the way to medical cures. When doctors use the latest technology from Butterfly IQ+, they Will be guided by real-time patient assessment.
“The Butterfly iQ+ is an innovative ultrasound solution that fits in the palm of your hand. We are very much looking forward to bringing this technology to market and seeing how it can help every patient in the UAE, a center of medical innovation in the Middle East.”
Abdul Latif Jameel Health CEO Akram Bouchenaki added: “Abdul Latif Jameel is addressing real needs in the real world today to create a better tomorrow. We are focused on healthcare inclusion, accelerating the delivery of modern healthcare to those who need it most.
“We believe in the true power of deep local knowledge, relationships and partnerships to bring about the best outcomes for the communities we serve. I am proud to partner with Cureleads who share our vision to improve life and livelihoods in the Global South. ”
-Finish-
About Abdul Latif Jameel Health
Backed by Abdul Latif Jameel, Abdul Latif Jameel Health is one of the most respected diversified family businesses and investors with a 75-year history, deep roots and established network, and presence in 30 countries/ With a multi-sectoral presence across the region, Abdul Latif Jameel Health is a trusted partner in realizing major innovations and opportunities in healthcare.
Abdul Latif Jameel Health reflects the Jameel family’s longstanding commitment to innovating for a better future through Community Jameel, an international organization that supports science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Health Machine Learning Clinic (Jameel Clinic) in September 2018 — which has quickly become MIT’s hub for artificial intelligence and healthcare — and the Abdul Latif Jameel Disease and the Jameel Institute, co-founded with Imperial College London in October 2019, use novel data analytics to reduce the risk of preventable diseases worldwide, most recently the COVID-19 pandemic in 2020, and strengthen the most vulnerable Sanitation systems in the environment.
Abdul Latif Jameel Health brings this commitment to the business environment, addressing today’s tangible real-world needs to create a better tomorrow. It focuses on healthcare inclusion in the Global South, accelerating access to modern healthcare for those who need it most by creating/growing new markets to distribute existing solutions and investing in the future of MedTech.
Jameel Investment Management Company (JIMCO) actively invests in innovative, early stage and breakthrough businesses and technologies, with the aim of actively shaping the future of cutting-edge medical technologies in core industries that drive the global economy through its investments across healthcare industries such as pharmaceuticals and vaccines, As well as emerging technologies in fintech, insurtech, electric vehicles and future mobility solutions.
For more information visit: https://aljhealth.com and our brand video. Media Contact: Email aljhealth@edelman.com. General inquiries: info@aljhealth.com. For adverse event reports or medical inquiries: safety@aljhealth.com
About Cureleads
Cureleads aspires to transform the lives of patients in the MENA region by improving access to key medicines to treat specific diseases, primarily cancer, neurology and rare diseases. In the next 10 years, the incidence of rare diseases in the Middle East and North Africa will become the highest in the world. At the same time, a powerful global convergence of biology and technology is driving enormous advances in medical therapies to treat these diseases. CURELEADS is committed to bringing these advancements to patients by partnering with cutting edge pharma/biotech innovators.
Cureleads is a GloCal company, a local team with decades of experience working for global pharmaceutical companies, we have used this experience to build a personal network of key stakeholders in business, government and academic medicine, not only in MENA, But the whole world. We leverage our experience and relationships to commercialize specialty medicines across the region while adhering to global standards of quality and ethical conduct, combining competence and ethics, biology and technology, innovation and tradition. Crucially, we focus on ‘doing business ethically’ to ensure appropriate and sustainable business outcomes. In addition to our own commercialization activities, we work with key regional distributors who provide optimal logistics capabilities, accounts receivable management and regulatory compliance.
For media inquiries, please contact info@cureleads.com. For more information visit: www.cureleads.com or the Cureleads LinkedIn page.
Copyright Notice and Disclaimer
© Meddist Company Ltd. (Addidas Health). all rights reserved. The Abdul Latif Jameel name, the Abdul Latif Jameel logo and the pentagon shape are trademarks or registered trademarks of Abdul Latif Jameel IPR Company Limited.
The term “Abdul Latif Jameel” broadly refers to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or consortium operated by an overall parent company, but simply refers to a group of distinct and entirely separate legal entities collectively known as Abdul Latif Jameel. Abdul Latif Jameel is not a business group within the meaning of section 1161(5) of the Companies Act 2006.
This document may contain forward-looking statements. Forward-looking statements are statements about matters other than historical facts, such as future results, events, activities, developments or circumstances or beliefs, plans or expectations of Abdul Latif Jameel or Abdul Latif Jameel entities or their respective management.
Forward-looking statements can often be identified by the use of words such as “expects,” “projects,” “anticipates,” “plans,” “estimates,” “believes,” “forecasts,” “intends,” “potential,” and similar terms, ‘possible ‘, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrase. However, the absence of such words does not mean that particular statements are not forward-looking.
Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are beyond the control of Abdul Latif Jameel Health or an Abdul Latif Jameel entity. Should any such expectations or assumptions prove to be incorrect, or should any such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ from those expressed or implied by forward-looking statements There are major differences in content.
In addition, any forward-looking statement speaks only as of the date it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel disclaims, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise . All forward-looking statements, whether communicated in writing, electronically or orally, by Abdul Latif Jameel Health, Abdul Latif Jameel or anyone acting on their behalf are qualified in their entirety by the foregoing cautionary statement.
no offer or solicitation
This communication is not a proxy or the solicitation of a proxy, consent or authorization, nor does it constitute an offer to sell or the solicitation of an offer to buy any securities, nor does it constitute the sale of any securities in any jurisdiction, pursuant to any under the securities laws of such jurisdictions, such offer, solicitation or sale would be unlawful prior to registration or qualification. No securities may be offered except by means of a prospectus or exemption complying with the requirements of Section 10 of the Securities Act.
Important note:
Butterfly iQ+ products are no Not yet registered/sold in all markets.
[1] The Butterfly iQ+ is a Class IIa/B/Class II/Class II/IIa portable ultrasound system designed for diagnostic imaging by trained healthcare professionals. Read and understand all cautions, warnings, and operating instructions before use.
[2] UAE Statistics Annual Report 2020 published by the UAE Ministry of Health and Prevention
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704652/
[4] https://www.globalmediainsight.com/blog/uae-population-statistics/
[5] https://u.ae/en/about-the-uae/fact-sheet
[ad_2]
Source link